alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › incretin-based-therapies

incretin-based-therapies

4 studies tagged incretin-based-therapies, dated 2014-03-07 to 2025-07-15. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Incretin-Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists-A Review 2025-07-15
  2. Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies 2023-05-05
  3. Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus 2015-10-03

Studies

4 studies carry this tag.

Date range

2014 to 2025

Top journals

  • Journal of diabetes investigation 2
  • Endocrine 1
  • Health science reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Incretin-Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists-A Review

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Health science reports 2025-07-15 Drug development

    Emerging evidence highlights disrupted insulin signaling in AD and, to a lesser extent, in PD, suggesting that insulin plays a key neuroprotective role.

  2. Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Journal of diabetes investigation 2023-05-05 Drug development

    Current evidence shows that incretin-based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.

  3. Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of diabetes investigation 2015-10-03 Drug development

    Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia.

  4. Extra-pancreatic effects of incretin-based therapies

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Endocrine 2014-03-07 Drug development

    Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and inhibits glucagon secretion in the pancreatic islets of Langerhans under hyperglycaemia.

All topic tags with their study counts